July 29, 2019
Bayer Yakuhin on July 26 filed its ophthalmic vascular endothelial growth factor (VEGF) inhibitor Eylea (aflibercept) for an additional indication of neovascular glaucoma (NVG) in Japan. NVG is a secondary glaucoma mainly characterized by retinal ischemia such as proliferative diabetic...read more